Therapeutic vaccines against hepatitis C virus

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis C virus (HCV) chronically infects 130-210 million people worldwide.
• Standard-of-care (SoC) therapy for HCV is often inadequate, expensive, and has significant side effects.
• While direct-acting antivirals (DAAs) offer improvements, research is shifting towards interferon- and ribavirin-free regimens and therapeutic vaccines.

Purpose of the Study:

• To review the roles of neutralizing antibodies (NAbs) and CD8(+) T-cells in developing therapeutic vaccines for HCV.
• To summarize key HCV epitopes recognized by CD8(+) T-cells.
• To discuss prospective therapeutic vaccine approaches for HCV.

Main Methods:

• Literature review of current HCV treatment and vaccine development strategies.
• Analysis of immune responses, including NAbs and CD8(+) T-cells, in the context of HCV infection.
• Identification and summary of relevant HCV epitopes for T-cell recognition.

Main Results:

• Current DAAs offer shorter treatment durations but still present challenges with side effects and cost.
• All-oral, interferon- and ribavirin-free regimens are emerging as the next generation of HCV treatments.
• Therapeutic vaccines aim to prevent HCV chronicity by inducing robust immune responses, rather than complete prevention.

Conclusions:

• Therapeutic vaccines for HCV are a critical area of ongoing research.
• Effective vaccines will likely rely on inducing broad CD4(+), CD8(+) T-cell, and NAb responses.
• Focusing on preventing chronic infection represents a realistic goal for HCV vaccine development.